Cytosorbents (CTSO) Stock Statistics & Valuation Metrics

Cytosorbents has a market cap or net worth of $64.37M. The enterprise value is $68.40M.

Cytosorbents has 62,500,000 shares outstanding. The number of shares has decreased by -2.65% in one year.

Cytosorbents’s return on equity (ROE) is -1.22 and return on invested capital (ROIC) is -72.96%.

The current PE Ratio of Cytosorbents is -1.74. Cytosorbents’s PEG ratio is 0.12.

In the last 12 months, Cytosorbents had revenue of 36.35M and earned -28.51M in profits. Earnings per share was -0.64.

In the last 12 months, operating cash flow was -18.49M and capital expenditures -681.16K, giving a free cash flow of -19.17M billion.

Cytosorbents pays an annual dividend of ―, resulting in a dividend yield of ―

Cytosorbents upcoming earnings date is May 6, 2025, TBA Not Confirmed.

Cytosorbents as a current ratio of 1.77, with Debt / Equity ratio of 206.22%

In the past 12 months, Cytosorbents has paid -813.74K in taxes.

Cytosorbents EV to EBITDA ratio is -1.84, with an EV/FCF ratio of -2.38.

Cytosorbents has $5.69M in cash and marketable securities with $172.50K in debt, giving a net cash position of $21.12M billion.

Gross margin is 61.92%, with operating margin of -85.86%, and net profit margin of -78.43%.

The average price target for Cytosorbents is $1.00, which is 11.43% higher than the current price. The consensus rating is Hold